Hypertension and microalbuminuria in hiv infected patients: beneficial effects of the treatment with telmisartan

Ucciferri et al. Retrovirology 2010, 7(Suppl 1):P64http://www.retrovirology.com/content/7/S1/P64 Hypertension and microalbuminuria in HIVinfected patients: beneficial effects of thetreatment with telmisartan Claudio Ucciferri*, Paola Mancino, Katia Falasca, Francesca Vignale, Jacopo Vecchiet From 16th International Symposium on HIV and Emerging Infectious DiseasesMarseille, France. 24-26 March 2010 statistically decreased at T1 (p = 0,006) and further on In HIV infected patients there is increasing evidence of T6 (p = 0,0001), whereas MDRD-GFR was statistically hypertension and microalbuminuria, two important risk augmented (p = 0,03). Cystatin-C, endothelin-1 and factors for renal and cardiovascular disease (CVD). Anti- VEGF were statistically reduced at T3 (p = 0,0001; p = hypertensive drugs inhibiting the renin-angiotensin sys- 0,01 and p = 0,0045 respectively) and at T6. TG, TCh, tem exert an antiproteinuric effect. Telmisartan, an LDL-C levels decreased with statistical significance at angiotensin II receptor blocker partial agonist of the T6 (p = 0,003; p = 0,03 and p = 0,02 respectively), while PPAR-g approved for the treatment of hypertension, HDL-C increased at T6 (p = 0,04). ESR, PCR and IL-18 seems to exert a nephro-protective effect independent of decreased at T6 (p = 0,04; p = 0,006 and p = 0,02 blood pressure reduction in the general population. Aim of the study was to evaluate kidney-protective effects oftelmisartan Telmisartan was well tolerated and effective to improvehypertension and lipid metabolism. Decreased microal- buminuria and cystatin-C with increased MDRD-GFR 8 Caucasian male HIV+ patients cART treated without are indicative of nephro-protective effects of telmisartan.
therapeutic changes for over 12 months and recent diag- Mechanisms causing microalbuminuria in HIV+ patients nosis of mild hypertension, were treated with telmisar- could be related to infection, chronic inflammation and tan 80 mg daily. They had suppressed viremia and CD4 endothelial dysfunction. Decreased endothelin-1 and cell count > 300 cell/ml up on 6 month, and microalbu- VEGF in this study may be related to an endothelial minuria >5 mg/l. Systolic (SBP) and diastolic (DBP) protective effect of telmisartan. These data confirm blood pressure, triglycerides (TGs), total cholesterol renal and endothelial protective effects of telmisartan (TCh), HDL (HDL-C) and LDL (LDL-C) cholesterol, CRP, ESR, microalbuminuria, MDRD-GFR, cystatin-C,IL-18, VEGF and endothelin-1 were measured at base- line (T0), one (T1), three (T3) and six months (T6). Allthe statistical analysis was performed with the SPSSAdvanced Statistical 7.5 Software.
doi:10.1186/1742-4690-7-S1-P64Cite this article as: Ucciferri et al.: Hypertension and microalbuminuria in HIV infected patients: beneficial effects of the treatment with Treatment with telmisartan improved SBP and DBP telmisartan. Retrovirology 2010 7(Suppl 1):P64.
values at T1 yet (p = 0,001). Microalbuminuria were * Correspondence: Infectious Disease Clinic, Department of Medicine and Science of Aging, “G.
d’Annunzio” University, Chieti, Italy 2010 Ucciferri et al; licensee BioMed Central Ltd.

Source: http://www.retrovirology.com/content/pdf/1742-4690-7-S1-P64.pdf